Skip to main content
. 2020 Dec 24;9(2):e1576. doi: 10.1002/mgg3.1576

FIGURE 1.

FIGURE 1

Probability of end‐stage renal disease for the heterozygous COL4A3/COL4A4 ATS patients compared to the recessive and X‐linked counterparts (Panel a) and for the heterozygous COL4A3/COL4A4 heterozygous carriers of truncating variants vs. those with missense substitutions in the glycine domains (Panel b)